WO2012142678A1 - Composition pour la perte de poids - Google Patents

Composition pour la perte de poids Download PDF

Info

Publication number
WO2012142678A1
WO2012142678A1 PCT/AU2012/000427 AU2012000427W WO2012142678A1 WO 2012142678 A1 WO2012142678 A1 WO 2012142678A1 AU 2012000427 W AU2012000427 W AU 2012000427W WO 2012142678 A1 WO2012142678 A1 WO 2012142678A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
vitamin
composition according
probiotic microorganisms
subject
Prior art date
Application number
PCT/AU2012/000427
Other languages
English (en)
Inventor
Kate BARRY
Sean HALL
Evan Hayes
Original Assignee
Fit-Bioceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011901524A external-priority patent/AU2011901524A0/en
Application filed by Fit-Bioceuticals Limited filed Critical Fit-Bioceuticals Limited
Priority to AU2012245002A priority Critical patent/AU2012245002A1/en
Publication of WO2012142678A1 publication Critical patent/WO2012142678A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A23L27/34—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/37—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • compositions comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol and uses thereof for promoting weight and/or fat loss in a subject.
  • the number of overweight and obese individuals has more than doubled over the past two decades.
  • the health problems and consequences associated with overweight and obese individuals are many and varied, including type 2 diabetes, gall bladder disease, hypertension, dyslipidaemia, insulin resistance, musculoskeletal problems, cardiovascular disease, atherosclerosis, some cancers, sleep apnoea, breathlessness, asthma, social isolation/depression and daytime sleepiness/fatigue.
  • Such health problems cause discomfort and pain and decrease the quality of life to the individual and are a costly clinical problem.
  • Treatment of overweight or obese individuals includes diet and exercise regimes. Unfortunately not all individuals are able to diet and/or exercise effectively due to factors such as sedentary lifestyles, the ready availability of fast foods and convenience foods leading to poor dietary selection, lack of free time, stress and depression. As a result many individuals are unable to reduce their weight and/or maintain a healthy weight. Some individuals choose to undergo surgery in an attempt to lose weight, for example by undergoing surgery to reduce the size of the stomach or the length of the bowels. Unfortunately, complications from surgery are common and the individual is required to modify their behaviour towards food to enhance the likelihood of a successful outcome.
  • compositions that promotes weight loss and/or fat loss in an individual.
  • the present inventors have found that a composition comprising one or more probiotic microorganisms, giutamine and at least one sugar alcohol promotes weight loss and/or fat loss in an individual.
  • composition comprising one or more probiotic microorganisms, giutamine and at least one sugar alcohol.
  • composition comprising one or more probiotic microorganisms, giutamine and at least one sugar alcohol for promoting weight loss and/or fat loss in a subject.
  • composition according to the first or second aspect may further comprise vitamin K.
  • the one or more probiotic microorganisms comprises Lactobacillus and/or Bifidobacterium.
  • the probiotic microorganisms comprise Lactobacillus acidophilus.
  • the probiotic microorganisms comprise Bifidobacterium lactis.
  • the probiotic microorganisms comprises Lactobacillus acidophilus and Bifidobacterium lactis.
  • the probiotic microorganisms in the composition may be in an amount of from about 1 billion to about 50 billion lU/mg. In one embodiment the probiotic microorganisms in the composition are in an amount of about 3 billion lU/mg.
  • the giutamine in the composition may be in an amount of from about 50 to about 600 lU/mg. In one embodiment the giutamine in the composition is in an amount of about 250 lU/mg.
  • the at least one sugar alcohol is xylitol, mannitol or sorbitol. In particular embodiments the at least one sugar alcohol is xylitol.
  • the xylitol in the composition may be in an amount of from about 10 to about 300 g/kg. In one embodiment the xylitol in the composition is in an amount of about 110 g/kg.
  • the composition further comprises vitamin K.
  • the vitamin K may be vitamin K1 and/or vitamin K2.
  • the vitamin K in the composition may be in an amount of from about 0.1 pg/mg to about 100 pg/mg. In one embodiment the vitamin K in the composition is in an amount of about 1 pg /mg.
  • composition further comprises vitamin D.
  • composition further comprises whey protein.
  • composition further comprises vitamin B.
  • composition further comprises polydextrose.
  • composition further comprises at least one medium chain triglyceride.
  • composition further comprises one or mqre enzyme.
  • the enzyme may be selected from the group consisting of protease, bromelain and papain.
  • the composition is in a form suitable for oral administration.
  • the composition is in the form of a liquid, a powder or a unit dosage form such as a tablet, capsule or caplet.
  • a method of promoting weight loss and/or fat loss in a subject comprising administering to the subject a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol.
  • composition is typically administered to the subject orally.
  • the composition is in the form of a liquid, a powder or a unit dosage form.
  • the unit dosage form may be a tablet, a capsule or a caplet. Typically between 1 and 5 unit dosage forms are administered per day.
  • a method of promoting a healthy immune system in a subject comprising administering to the subject a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol.
  • the composition is typically administered to the subject orally.
  • the composition is in the form of a liquid, a powder or a unit dosage form.
  • the unit dosage form may be a tablet, a capsule or a caplet. Typically between 1 and 5 unit dosage forms are administered per day.
  • the oral composition as defined above may be in the form of a food stuff or beverage, or suitable for administering with a food stuff or beverage.
  • composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol in the manufacture of a medicament for promoting weight loss and/or fat loss in a subject.
  • composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol in the manufacture of a medicament for promoting a healthy immune system in a subject.
  • an element means one element or more than one element.
  • sucrose alcohol or “sugar alcohols” is understood to refer to those compounds with the general formula H(HCHO) n+ iH and which can be administered to a subject. A person skilled in the art will appreciate that the term does not include the sugar alcohol glycol.
  • probiotic microorganisms is to be given its broadest construction and is understood to refer to any live microorganisms which when administered in an effective amount promotes a health benefit.
  • prebiotic is to be given its broadest construction and is understood to refer to any non-digestible substance that stimulates the growth and/or activity of bacteria, in particular probiotic bacteria, in the digestive system.
  • the terms “promote” and “promoting” and variations thereof as used herein refer to the ability of a composition of the present disclosure to achieve or assist in achieving a benefit, either directly or indirectly, in relation to weight loss and/or fat loss, the health of the gastrointestinal tract, the health of the immune system and/or diseases associated therewith; or to improve the ability to achieve or assist in achieving a measurable benefit, either directly or indirectly, in relation to weight loss and/or fat loss, the health of the gastrointestinal tract, the health of the immune system and/or diseases associated therewith; or otherwise prevent, hinder, retard, or reverse the deterioration in the health of a subject in any way whatsoever.
  • promote promote
  • a derivative of vitamin D 3 is understood to include compounds that are formed from a parent compound by chemical reaction(s).
  • a derivative of vitamin D 3 is a compound formed by a chemical reaction with vitamin D 3 .
  • precursors or precursors
  • a precursor of vitamin D 3 forms vitamin D 3 via chemical reaction(s) or metabolic process(es).
  • “food”, “foods”, “beverage” or “beverages” includes but is not limited to health foods, functional foods and foods for specified health use. When such food or beverage of the present disclosure is used for subjects other than humans, the term can be used to include a feedstuff.
  • the term “subject” includes humans, primates, livestock animals (eg. sheep, pigs, cattle, horses, donkeys), laboratory test animals (eg. mice, rabbits, rats, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. foxes, kangaroos, deer). Typically, the subject is a human or a laboratory test animal. Even more typically, the subject is a human.
  • Embodiments of the present disclosure provide compositions comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol.
  • the compositions promote weight loss and/or fat loss in a subject.
  • the compositions may be used as meal replacements or alternatively in addition to meals as part of a calorie controlled diet/weight loss regime.
  • compositions of the disclosure are also useful for managing diseases and/or disorders that are associated with excessive calorie intake, such as obesity, metabolic syndrome and diseases and conditions related thereto.
  • compositions may promote a healthy immune system thereby reducing the risk of autoimmune disease, reducing inflammation, and promoting the health of the gastrointestinal tract thereby promoting healthy digestion and absorption of nutrients in a subject.
  • compositions may promote an improved mood state and/or boost the metabolism and assist in balancing the appetite of a subject.
  • compositions may promote the health of a subject by reducing the risk of hypothyroidism.
  • compositions of the present disclosure may also assist in reducing or inhibiting bone decay in a subject, thereby decreasing the pain associated with the effects of carrying extra weight.
  • compositions of the present disclosure seek to not only address the issue of weight loss and or fat loss but also to reduce systematic inflammation and stress in the gastrointestinal tract thereby promoting an improvement in the health of the gastrointestinal tract, promoting weight loss and/or fat loss and promoting additional health benefits.
  • Compositions comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol work synergistically promoting bacterial growth in the gut because the glutamine and at least one sugar alcohol nourish the probiotic microorganisms during proliferation.
  • BMI Body Mass Index
  • compositions may reduce systemic inflammation and promote the health of the gastrointestinal tract and therefore assist in preventing and/or promoting the improvement of conditions associated with systemic inflammation.
  • Dysbiosis is a condition that causes microbial imbalances on or within the body.
  • Dysbiosis can cause major problems in the gastrointestinal tract or on the skin, and has been associated with inflammatory bowel disease, chronic fatigue syndrome, poor oestrogen clearance and compromised digestion which can reduce the absorption of nutrients.
  • Dysbiosis can also lead to leaky gut and can comprise vitamin K in a subject.
  • the probiotic microorganisms in accordance with embodiments of the present disclosure may reduce dysbiosis thereby promoting absorption of B vitamins and vitamin K.
  • the compositions of the present disclosure may comprise any one or more probiotic microorganisms.
  • the one or more probiotic microorganisms may be present in the composition as specially selected strains as a culture concentrate or as part of a multiple strain blend with a variety of excipients.
  • the one or more probiotic microorganisms may include but are not limited to one or more of a strain of Lactobacillus, Bifidobacterium, Streptococcus Saccharomyces, Bacillus, Enterococcus, Bacteroides or Propionibacterium.
  • the Lactobacillus may be one or more of, but is not limited to, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus reuteri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus gasseri or Lactobacillus sporogenes.
  • the Lactobacillus is Lactobacillus acidophilus.
  • the Bifidobacterium may be one or more of, but is not limited to, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium Lafti, Bifidobacterium breve or Bifidobacterium lactis. In one embodiment the Bifidobacterium is Bifidobacterium lactis.
  • the Streptococcus may be one or more of, but is not limited to, Streptococcus thermophilus, Streptococcus faecium, or Streptococcus salivarius.
  • the Saccharomyces may be one or more of, but is not limited to, Saccharomyces cerevisiae or Saccharomyces boulardii.
  • the Bacillus may be one or more of, but is not limited to, Bacillus coagulans, Bacillus cereus, Bacillus clausii, or Bacillus pumilus.
  • the Enterococcus may be, but is not limited to, Enterococcus faecium.
  • the amount of one or more probiotic microorganisms present in the compositions may be between about 1 billion to about 100 billion lU/mg, or more typically between about 2 billion to about 5 billion lU/mg.
  • the composition may comprise about 2.5 billion lU/mg, 3.0 billion lU/mg, 3.5 billion lU/mg, 4.0 billion lU/mg or 4.5 billion lU/mg of the one or more probiotic microorganisms.
  • the glutamine may be present in the composition in the form of a salt or derivative.
  • the amount of glutamine present in the composition may be between about 1 lU/mg and about 1000 lU/mg, or more typically between about 50 lU/mg and about 600 lU/mg.
  • the composition may comprise about 100 lU/mg, 150 lU/mg, 200 lU/mg, 250 lU/mg, 300 lU/mg, 350 lU/mg, 400 lU/mg, 450 lU/mg, 500 lU/mg or 550 of glutamine.
  • compositions of the present disclosure comprise at least one sugar alcohol.
  • the at least one sugar alcohol is typically selected from a sugar alcohol that also functions as a sweetener.
  • the at least one sugar alcohol may include, but is not limited to, one or more of glycerol, erythritol, xylitol, mannitol, sorbitol, isomalt, maltitol, lactitol or polyglycitol.
  • the at least one sugar alcohol is sorbitol.
  • the at least one sugar alcohol is mannitol.
  • the at least one sugar alcohol is xylitol.
  • the xylitol may be present in the composition in the form of a salt or derivative.
  • the amount of xylitol present in the composition may be between about 1 g/kg and about 1000 g/kg, or more typically between about 10 g/kg and about 300 g/kg.
  • the composition may comprise about 20 g/kg, 30 g/kg, 40 g/kg, 50 g/kg, 60 g/kg, 70 g/kg, 80 g/kg, 90 g/kg, 100 g/kg, 110 g/kg, 120 g/kg, 130 g/kg, 140 g/kg, 150 g/kg, 160 g/kg, 170 g/kg, 180 g/kg, 190 g/kg, 200 g/kg, 210 g/kg, 220 g/kg, 230 g/kg, 240 g/kg, 250 g/kg, 260 g/kg, 270 g/kg, 280 g/kg or 290 g/kg of xylitol.
  • the composition may further comprise vitamin K.
  • the vitamin K may be vitamin Ki and/or vitamin K 2 .
  • the vitamin K is vitamin K2.
  • the vitamin K may be present in the form of suitable precursors, derivatives or analogues thereof.
  • the body does not store vitamin K and therefore it is an essential vitamin that needs to be continuously ingested.
  • Vitamin K 2 is produced by probiotics and some vegetables such as broccoli, however vitamin K 2 produced by probiotics is not always readily absorbed in the gut and the harmful bacteria in the gut does not permit vegetables to be digested effectively enough to ' extract sufficient vitamin K 2 from such foods.
  • the one or more probiotic microorganisms in the compositions of the present disclosure harmonise the gut of an overweight or obese individual thereby allowing vitamin K to be more effectively extracted from food.
  • the combination of one or more probiotic microorganisms and vitamin K (in particular vitamin K 2 ) in the compositions promote the proliferation of the beneficial bacteria and promote the absorption of vitamin K 2 .
  • the amount of vitamin K present in the composition may be between about 0.1 Mg/mg and about 100 Mg/mg, or more typically between about 0.2 ⁇ /mg and about 5 ⁇ /mg w/w.
  • the composition may comprise about 0.4 Mg/mg, 0.6 Mg/mg, 0.8 M /mg, 1.0 Mg/mg, 1.2 M /mg, 1.4 Mg/mg, 1.6 Mg/mg, 1.8 Mg/mg, 2.0 Mg/mg, 2,2 Mg/mg, 2.4 Mg/mg, 2.6 Mg/mg, 2.8 Mg/mg, 3.0 Mg/mg, 3.2 Mg/mg, 3.4 Mg/mg, 3.6.
  • Fat cells can sequester vitamin D3 which can result in overweight and obese individuals suffering from vitamin D3 deficient related conditions, for example low bone density, inflammation, autoimmune diseases, poor immunity to colds and flu, depression, and cancer. Accordingly, in some embodiments vitamin D is added to the compositions to assist in replacing the vitamin D sequestered by fat cells.
  • the vitamin D may be present as vitamin D 2 and/or D3.
  • the compositions comprise vitamin D3 (cholecalciferol).
  • the vitamin D3 may be in the form of any suitable precursor, derivative or analogue thereof;
  • the composition comprises vitamin D 2 (ergocalciferol), or metabolites, analogues or derivatives thereof.
  • compositions may further comprise a fibre and/or a prebiotic.
  • compositions further comprise polydextrose which acts both as a source of a fibre and a prebiotic.
  • the fibre and prebiotic may be inulin, fructooligosaccharides (FOS), xylooligosaccharides (XOS) and/or galactooligosaccharides (GOS).
  • FOS fructooligosaccharides
  • XOS xylooligosaccharides
  • GOS galactooligosaccharides
  • At least one enzyme such as but not limited to, protease (peptidase), bromelain and papain and/or at least one medium chain triglyceride (medium- chain (6 to 12 carbons) fatty acid esters of glycerol) may be added to the compositions.
  • the at least one medium chain triglyceride may be selected from the group consisting of caproic acid (C6), caprylic acid (C8), capric acid (C10) and lauric acid (C12).
  • C6 caproic acid
  • C8 caprylic acid
  • capric acid C10
  • lauric acid C12
  • a combination of at least one medium chain triglyceride and at least one enzyme in the compositions of the invention promotes the digestion of the at least medium chain triglyceride and ensures that the medium chain triglyceride is effectively utilised as energy thereby further promoting weight loss and/or fat loss.
  • compositions may comprise protein.
  • the protein may be whey protein, however a person skilled in the art will appreciate that other protein sources may also be used.
  • the whey protein may be in the form of a concentrate, an isolate, and/or a hydrolysate.
  • the whey protein is typically obtained from cow's milk, however those skilled in the art will appreciate that whey protein sourced from other milk may be used.
  • the whey protein may comprise at least one of alpha iactalbumin, beta lactoglobulin, bovine serum albumin immunoglobulins and glycomacropeptides or mixtures thereof.
  • compositions of the present disclosure may further comprise vitamins and/or minerals and/or amino acids.
  • the vitamins and/or minerals may be one or more vitamins or minerals indicated for weight loss and/or appetite control.
  • the vitamins and minerals may be selected from, but not limited to: vitamins A, Bi, B2, B 3 , B5, Be, B9, B12, C, D, E and calcium, chromium, copper, fluorine, iodine, iron, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, sodium and zinc.
  • amino acids may be selected from, but are not limited to: alanine, arginine, aspartic acid, cystine, glycine, histidine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan and tyrosine.
  • compositions may be used as meal replacements or supplements. Alternatively, the compositions may form part of a calorie controlled diet. The methods and compositions of the disclosure may form part of a weight management program in a subject in need thereof. The compositions may be taken before, during, or after a meal and/or in between meals where necessary. In some embodiments the serving size of the composition may be between about 1 g and about 100 g, or between about 5 g and about 50 g, or between about 25 g and about 35 g, or about 26 g, 27 g, 28 g, 29 g, 30 g, 31 g, 32 g, 33 g or 34 g.
  • compositions will depend on a number of factors such as the particular composition being administered, the age, body weight, general health, sex and dietary requirements of the subject, as well as any drugs or agents used in combination or coincidental with the compositions. Based on the teaching herein those skilled in the art will, by routine trial and experimentation, be capable of determining suitable dosage regimes on a case-by-case basis.
  • compositions may be provided to the user, for example, in a liquid form, a powder form or as a solid unit dosage form such as a tablet, capsule or caplet.
  • the compositions may be added in powder form by the user to any type of drink or food product (for example water, fruit juice or yoghurt) and consumed there after.
  • the compositions may simply be consumed as a powder in the absence of a drink or additional food product.
  • the composition may be conveniently presented and consumed in a dosage form prepared by any of the methods well known in the art.
  • the method may include the step of bringing the components of the oral composition into association with a carrier which constitutes one or more accessory ingredients.
  • oral compositions are prepared by uniformly and intimately bringing into association the components of the composition with a liquid carrier or finely divided solid carrier, or both and then, if necessary, shaping the product into the desired composition.
  • composition may be conveniently incorporated in a variety of food and/or beverage products, nutraceutical products, pharmaceuticals and over-the- counter formulations.
  • the food may be a solid form such as a powder, or a liquid form.
  • beverages or foods include, but are not limited to water-based, milk-based, yoghurt-based, other dairy-based, milk-substitute based such as soy milk or oat milk, or juice-based beverages, water, soft drinks, carbonated drinks, and nutritional beverages, (including a concentrated stock solution of a beverage and a dry powder for preparation of such a beverage); baked products such as crackers, breads, muffins, rolls, bagels, biscuits, cereals, bars such as muesli bars, health food bars and the like, dressings, sauces, custards, yoghurts, puddings, prepackaged frozen meals, soups and confectioneries.
  • compositions of the disclosure may be used in conjunction with other treatments directed to other diseases.
  • the compositions of the invention may be used as part of a treatment regime or combination therapy, wherein the role of the composition is to promote weight loss and/or fat loss.
  • the composition may be administered to a subject undergoing drug treatment for heart disease, wherein the composition assists in weight loss and/or fat loss.
  • Example 1 Oral powder composition
  • a typical powder composition for oral administration is prepared by combining the following components:
  • Vitamin K 0.156 g/Kg (optional)
  • alpha lactalbumin alpha lactalbumin, beta lactoglobulin, bovine serum albumin, immunoglobulins (IgG) and glycomacropeptides
  • Vitamin A 0.060 g/Kg
  • Vitamin Bi as thiamine hydrochloride
  • Vitamin B 2 (as riboflavin) 0.027 g/Kg
  • Vitamin BY (as nicotinamide) 0.156 g/Kg
  • Vitamin Be (as pyridoxine hydrochloride) 0.030 g/Kg
  • Vitamin B (as biotin) 0.047 g/Kg
  • Vitamin B9 (as folic acid) 0.031 g/Kg
  • Vitamin B12 0.003 g/Kg
  • Vitamin C (ascorbic acid) 0.625 g/Kg
  • Vitamin D3 0.016 g/Kg Vitamin E (d-alpha tocopheryl succinate) 0.189 g/Kg
  • Chromium Chromium Pieolinate 2%) 0.318 g/Kg
  • the dosage is 32 g of the resulting powder (typically dissolved in 200 mL water or other liquid) to be taken once to three times daily.
  • Example 2 Oral powder composition
  • An exemplary oral composition in accordance with the present disclosure comprises:
  • Vitamin A 625.000 IU 1953.125 IU
  • Vitamin D3 50.000 IU 156.250 IU
  • Vitamin B12 (Cyanocobalamin) 1.000 meg 3.125 meg
  • Pantothenic Acid (Vitamin B5) 0.800 mg 2.500 mg Ascorbic Acid 20,000 mg 62.500 mg
  • Vitamin E 5.000 mg 15.625 mg
  • Immunoglobulins (IgG) 586.000 mg 1831.250 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne généralement l'utilisation de compositions comprenant un ou plusieurs micro-organismes probiotiques, de la glutamine et au moins un polyol et des utilisations de celles-ci pour stimuler la perte de poids et/ou de graisse chez un sujet.
PCT/AU2012/000427 2011-04-21 2012-04-23 Composition pour la perte de poids WO2012142678A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012245002A AU2012245002A1 (en) 2011-04-21 2012-04-23 Weight loss composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011901524A AU2011901524A0 (en) 2011-04-21 Weight loss composition
AU2011901524 2011-04-21

Publications (1)

Publication Number Publication Date
WO2012142678A1 true WO2012142678A1 (fr) 2012-10-26

Family

ID=47040982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/000427 WO2012142678A1 (fr) 2011-04-21 2012-04-23 Composition pour la perte de poids

Country Status (2)

Country Link
AU (1) AU2012245002A1 (fr)
WO (1) WO2012142678A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128259A1 (fr) * 2013-02-22 2014-08-28 Bill, Anja Composition pharmaceutique destinée au traitement du syndrome d'épuisement
EP3006027A1 (fr) * 2014-10-08 2016-04-13 Professional Dietetics S.p.A. Compositions comprenant des acides aminés destinées à être utilisées dans le traitement de l' etat inflammatoire systemique associe a des accidents cérébrovasculaires chez des patients souffrant de dysphagie
BE1025428B1 (nl) * 2018-01-23 2019-02-14 Omega Pharma Innovation & Development Nv Voedingssupplement en gebruiken daarvan
CN111254087A (zh) * 2019-12-27 2020-06-09 杭州娃哈哈科技有限公司 一株具有增强免疫力功能的高黏附性能瑞士乳杆菌及其应用
CN111449183A (zh) * 2019-06-24 2020-07-28 广州维汝堂营养健康咨询有限公司 一种具有减脂功能的益生菌固体饮料

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057726A1 (fr) * 1999-03-29 2000-10-05 The Nutrasweet Company ALIMENTS FONCTIONNELS COMPRENANT UN ESTER DE 1-METHYLE N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE
DE202006017823U1 (de) * 2006-11-21 2007-02-15 Ionescu, John G., Dr. Diätisches Lebensmittel mit erhöhter freie Radikale bindender Wirkung
US20070116826A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition with Probiotics/Prebiotics and Compositions Sweetened Therewith
US20070134391A1 (en) * 2005-11-23 2007-06-14 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057726A1 (fr) * 1999-03-29 2000-10-05 The Nutrasweet Company ALIMENTS FONCTIONNELS COMPRENANT UN ESTER DE 1-METHYLE N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE
US20070116826A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition with Probiotics/Prebiotics and Compositions Sweetened Therewith
US20070134391A1 (en) * 2005-11-23 2007-06-14 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith
DE202006017823U1 (de) * 2006-11-21 2007-02-15 Ionescu, John G., Dr. Diätisches Lebensmittel mit erhöhter freie Radikale bindender Wirkung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Adult probiotic plus total intestinal & digestive support", PROVEN(R) PROBIOTICS, Retrieved from the Internet <URL:http://www.provenprobiotics.co.uk/adult-probiotic-plus-total-intestinal-and-digestive-support> [retrieved on 20120604] *
"IsoWhey Complete", ISOWHEY, Retrieved from the Internet <URL:http://www.isowhey.com.au/product/isowhey-complete> [retrieved on 20120531] *
"Products - Whey Less", WHEY LESSTM, Retrieved from the Internet <URL:http://www.wheyless.com.au/page/products> [retrieved on 20120531] *
OOI LG ET AL.: "Cholesterol-lowering effects ofprobiotics and prebiotics: a review of in vivo and in vitro findings", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 11, 17 June 2010 (2010-06-17), pages 2499 - 2522, XP002665634, DOI: doi:10.3390/IJMS11062499 *
ROBERFROID M. ET AL.: "Prebiotic effects: metabolic and health benefits", BRITISH JOURNAL OF NUTRITION, 4 October 2010 (2010-10-04), pages S1 - S63, Retrieved from the Internet <URL:http://journals.cambridge.org/download.php?file=%2F10954_A45E6D71CD5EF2272A71EA730EA3BA6B_journals__BJN_BJN104_S2_S0007114510003363a.pdf&cover=Y&code=8c4224fe63b2aa14d298f403f4d38dc7> [retrieved on 20120604] *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128259A1 (fr) * 2013-02-22 2014-08-28 Bill, Anja Composition pharmaceutique destinée au traitement du syndrome d'épuisement
EP3006027A1 (fr) * 2014-10-08 2016-04-13 Professional Dietetics S.p.A. Compositions comprenant des acides aminés destinées à être utilisées dans le traitement de l' etat inflammatoire systemique associe a des accidents cérébrovasculaires chez des patients souffrant de dysphagie
WO2016055948A1 (fr) * 2014-10-08 2016-04-14 Professional Dietetics S.P.A. Compositions comprenant des acides aminés à utiliser dans le traitement d'accident vasculaire cérébral de patients atteints de dysphagie
KR20170057308A (ko) * 2014-10-08 2017-05-24 프로페셔날 디에테틱스 에스.피.에이. 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물
US9707198B2 (en) 2014-10-08 2017-07-18 Professional Deitetics S.p.A. Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia
AU2015329581B2 (en) * 2014-10-08 2019-02-07 Professional Dietetics S.P.A. Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia
KR102077374B1 (ko) * 2014-10-08 2020-02-13 프로페셔날 디에테틱스 에스.피.에이. 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물
BE1025428B1 (nl) * 2018-01-23 2019-02-14 Omega Pharma Innovation & Development Nv Voedingssupplement en gebruiken daarvan
EP3513665A1 (fr) * 2018-01-23 2019-07-24 Omega Pharma Innovation and Development NV Complément alimentaire et ses utilisations
CN111449183A (zh) * 2019-06-24 2020-07-28 广州维汝堂营养健康咨询有限公司 一种具有减脂功能的益生菌固体饮料
CN111254087A (zh) * 2019-12-27 2020-06-09 杭州娃哈哈科技有限公司 一株具有增强免疫力功能的高黏附性能瑞士乳杆菌及其应用
CN111254087B (zh) * 2019-12-27 2021-12-17 杭州娃哈哈科技有限公司 一株具有增强免疫力功能的高黏附性能瑞士乳杆菌及其应用

Also Published As

Publication number Publication date
AU2012245002A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
ES2605453T3 (es) Suplemento de la dieta maternal
US10471084B2 (en) Composition and method for treating acute respiratory tract infections
EP2658560A1 (fr) Composition nutritionnelle comprenant une fibre et des probiotiques pour la réduction des symptômes intestinaux liés au stress
WO2002039834A1 (fr) Composition nutritionnelle destinee a une maladie immunitaire
AU2002221860A1 (en) Nutritional composition for an immune condition
EP2945494B1 (fr) Composition d&#39;aliment pour bébés comprenant des bactéries viables produisant de l&#39;acide propionique et des bacteries viables produisant de l&#39;acide lactique
US20130280225A1 (en) Fiber and probiotics for reducing intestinal symptoms related to stress
EP1513541A2 (fr) Procede et composition destines a empecher ou a remedier aux symptomes de malabsorption
EP2658558A1 (fr) Fibre et probiotiques destinés à atténuer les symptômes intestinaux liés au stress chronique
JP2016505024A5 (fr)
ES2780690T3 (es) Composiciones nutricionales adaptadas a la edad con un contenido variable de proteínas
WO2012142678A1 (fr) Composition pour la perte de poids
EP2165713A1 (fr) Lactosérum améliorant la function du thymus
AU2016100501A4 (en) Probiotic compositions for weight management
AU2014100089A4 (en) Weight loss composition
WO2023176951A1 (fr) Composition de lutte contre la prolifération de bactéries collinsella et son utilisation
EP4059354A1 (fr) Combinaison synergique de probiotiques et de prébiotiques produisant de l&#39;acide butyrique
Mc Donagh et al. Milk and dairy products for better human health
AU2018222626A1 (en) Nutritional compositions with partially hydrolysed proteins for use in inducing glucose and/or insulin response(s) close to the ones observed with human milk
Jortberg et al. NUTRITION, MALNUTRITION, AND PROBIOTICS
McNally Nutrition, Malnutrition, and Probiotics
Singh DAIRY NUTRACEUTICALS AND FUNCTIONAL DAIRY FOODS: CURRENT STATUS, ISSUES AND CHALLENGES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12774102

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012245002

Country of ref document: AU

Date of ref document: 20120423

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 12774102

Country of ref document: EP

Kind code of ref document: A1